Chondrosarcomas (CHS) are considered as radio-resistant tumors requiring high-dose radiation therapy (RT). Skull base CHS are a validated indication for protontherapy. CHS from other anatomic sites are systematically contra-indicated for RT on an institution-dependent way, regardless of grade and quality of resection. The main objective of our study was to assess the impact of RT in extracranial CHS. Patients were extracted from the CONTICABASE, the database from the French Sarcoma Group (where all samples are reviewed for proper diagnosis), and additional data from the Rare Cancer Network were considered. All consecutive non metastatic extracranial CHS treated in a curative intent were included, regardless of RT. Between 2005 and 2014, 226 patients (125 men, 55%; median age 52 [range 11-90]), met inclusion criteria. Performance status was 0 in 50%, 1 in 46% and 2 in 4% of patients. ASA operability score was 0-1 in 65%, 2 in 20%, or >2. Primary site was a limb in 57%, thorax/spine in 24%, head and neck in 10% and abdomen/pelvis in 9%. It affected bone in 58% or soft-tissues in 42%. Grade was 1, 2, and 3 in 43%, 42%, and 15%; respectively. CHS was myxoïd, mesenchymal, dedifferentiated, periosteal in 28%, 10%, 5%, or 4%, respectively and NOS/other in most cases (53%). Surgery was performed in 89% with en bloc resection, and 76% of patients were considered as R0. RT was performed in 85 (37,6%) patients combined to surgery or as exclusive local treatment. Among irradiated patients 46 (54%), 18 (21%), 15 (18%) and 6 (7%) were grade 2, 1, 3 and unclassified respectively. Mean dose was 54Gy (range 26-70Gy). Three-dimensional RT, Intensity-modulated RT and protontherapy were used in 71%, 24% and 5% respectively. Thirty-nine (17%) patients had adjuvant chemotherapy. With a median follow-up period of 54,5 months (range 1-532), there were 84 (37,1%) relapses including 49 local relapses within median 48 months, 13 regional within 71 months, and 65 metastatic ones within 42 months. At last follow-up, 56% of the patients were alive without disease; and 11% and 29% of the patients were alive or dead with disease, respectively. Of the 62 locoregional relapsing patients, there were 15 (24%) in the irradiated vs 47 (76%) in the non-irradiated patients. Late grade 3 or more toxicity was noted in 3 patients. Extracranial chondrosarcoma is a rare entity but this large database study seems to show that these patients have a better outcome when RT (postoperative or exclusive) is administered.